Ali Salehi Farid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8681849/publications.pdf

Version: 2024-02-01

15	110	5	9
papers	citations	h-index	g-index
15	15	15	118
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study. Journal of the American Academy of Dermatology, 2021, 84, 1098-1100.	0.6	28
2	Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial. Journal of Dermatological Treatment, 2022, 33, 284-290.	1.1	13
3	Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatologic Therapy, 2021, 34, e14633.	0.8	11
4	Adverse outcome and severity of <scp>COVID</scp> â€19 in patients with autoimmune bullous diseases: A historical cohort study. Dermatologic Therapy, 2022, 35, .	0.8	10
5	Evaluating the efficacy and safety of topical sirolimus 0.2% cream as adjuvant therapy with pulsed dye laser for the treatment of port wine stain: A randomized, doubleâ€blind, placeboâ€controlled trial. Journal of Cosmetic Dermatology, 2021, 20, 2498-2506.	0.8	7
6	Current status and prospects for the diagnosis of pemphigus vulgaris. Expert Review of Clinical Immunology, 2021, 17, 819-834.	1.3	7
7	Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital. International Immunopharmacology, 2020, 89, 107093.	1.7	6
8	Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus. International Journal of Dermatology, 2022, 61, e14-e17.	0.5	5
9	Oral simvastatin combined with narrowband <scp>UVB</scp> for the treatment of psoriasis: A randomized controlled trial. Dermatologic Therapy, 2021, 34, e15075.	0.8	5
10	Treatment of pemphigus patients in the <scp>COVID</scp> â€19 era: A specific focus on rituximab. Dermatologic Therapy, 2020, 33, e14188.	0.8	4
11	Paradoxical worsening of pemphigus after rituximab presenting as figurate bullous eruption. British Journal of Dermatology, 2021, 185, e2.	1.4	4
12	Investigating expression pattern of eight immuneâ€related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatologic Therapy, 2020, 33, e14380.	0.8	3
13	Comparing efficacy and safety of potassium hydroxide 5% solution with 5-fluorouracil cream in patients with actinic keratoses: a randomized controlled trial. Journal of Dermatological Treatment, 2022, 33, 1376-1382.	1.1	3
14	Factors associated with the healing time of pemphigus vulgaris oral lesions: A prospective study. Oral Diseases, 2023, 29, 2248-2255.	1.5	3
15	Rituximab monotherapy in mild pemphigus. Journal of Dermatological Treatment, 2022, 33, 1784-1786.	1.1	1